CLEO DIAGNOSTICS LTD — Investor Relations & Filings

Cleo Diagnostics Ltd is a medical technology company focused on the development and commercialization of a novel blood-based diagnostic platform for the early detection of ovarian cancer. The company's core technology utilizes a proprietary protein biomarker, CXCL10, combined with a specialized algorithm to identify the presence of malignancy with high sensitivity and specificity. Unlike traditional screening methods such as CA-125, the CLEO platform is designed to detect ovarian cancer in its earliest stages, potentially improving patient outcomes through timely intervention. The diagnostic suite aims to provide clinicians with a reliable, non-invasive tool for triage and screening, addressing a significant unmet need in women's health. The company focuses on clinical validation and regulatory approval to integrate its testing solutions into global diagnostic workflows.